MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Molecular Interventions 6:132-136, (2006)
© American Society for Pharmacology and Experimental Therapeutics
10.1124/mi.6.3.3
This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Podgorski, I.
Right arrow Articles by Sloane, B. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Podgorski, I.
Right arrow Articles by Sloane, B. F.

Viewpoint

Loss of Caspase-8 in Tumor Cells: Mechanism to Overcome Integrin-Mediated Death?

Izabela Podgorski and Bonnie F. Sloane

Department of Pharmacology and Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201

SUMMARY

Successful metastasis is determined by the ability of tumor cells to invade surrounding tissue, survive in the circulation, extravasate, arrest, and proliferate within the secondary organ. During this process, mutations in oncogenes and tumor suppressor genes lead to genetic instability, which bestows tumor cells with a selective growth advantage and aids the acquisition of the malignant phenotype. Altered expression and activity of various components of the apoptotic pathway, including receptors, ligands, adaptors, and caspases, can contribute to malfunction of the apoptotic machinery and, ultimately, to a more malignant phenotype. The expression of caspase-8, a key apoptotic factor involved in both the extrinsic and the intrinsic apoptotic pathways, is very frequently lost in high-risk neuroblastomas, the most common group of early childhood tumors. Stupack et al. report a much higher incidence of apoptosis in caspase-8+, locally invasive extratumoral cells as compared with that of caspase-8– cells. Conversely, knockdown of cas-pase-8 expression by RNA interference promotes metastasis but has no effect on primary tumor growth. Caspase-8-expressing neuroblastomas undergo apoptosis in a caspase-8-dependent manner that is independent of death receptor activation but rather might be controlled by integrin-mediated death (IMD), a process that occurs in adherent cells and that is distinct from anoikis, a form of programmed cell death resulting from a loss of integrin-mediated cell-matrix contact.

Successful metastasis is determined by the ability of tumor cells to invade surrounding tissue, survive in the circulation, extravasate, arrest, and proliferate within the secondary organ. During this process, mutations in oncogenes and tumor suppressor genes lead to genetic instability, which bestow tumor cells with a selective growth advantage and aid the acquisition of the malignant phenotype (1). At the core of the metastatic process are the reciprocal interactions between the tumor cells and their microenvironment, as mediated by direct cell-cell contact or cytokine and growth factor signaling. The complexity of the crosstalk among tumor cells, stromal cells, and immune cells determines the response of the host microenvironment, which in turn modifies the invasive behavior of tumor cells. During metastasis, cells leave their "familiar neighborhoods" and in "foreign territory" they rely on interactions with extracellular matrix (ECM) to sense their surroundings (2). The ECM is a dynamic environment, varying from tissue to tissue, as well as at different times and states within a single tissue. The interaction of heterodimeric cell-surface receptors called integrins with the ECM transduces signals between the cells and the ECM (Figure 1Go). These matrix-initiated signals profoundly affect many cellular functions, including cell survival, proliferation, polarity, motility, differentiation, and even cell proliferation vs survival (3). Cancer cells have the ability to switch the types of integrins they express in order to overcome death signals and to activate pro-survival pathways (4); such resistance to apoptotic signals represents an important aspect of tumor progression, metastasis, and resistance to chemotherapy.


Figure 1
View larger version (42K):
[in this window]
[in a new window]
  		Figure 1. The integrin receptors and their major ECM ligands. Each heterodimeric transmembrane integrin receptor consists of one {alpha} and one ß subunit. {alpha} subunits: Figure 1 {alpha}1, Figure 1{alpha}2, Figure 1{alpha}3, Figure 1{alpha}4, Figure 1{alpha}5, Figure 1{alpha}6, Figure 1{alpha}7, Figure 1{alpha}8, Figure 1{alpha}9, Figure 1{alpha}10, Figure 1{alpha}11, Figure 1{alpha}v; ß subunits: Figure 1ß1, Figure 1ß3, Figure 1ß4, Figure 1ß5, •ß6, Figure 1ß7, Figure 1ß8. Composition of each subunit determines ligand specificity. Figure depicts seventeen distinct integrins and their binding preferences for collagen, laminin, tenascin, fibronectin, and vitronectin.

 
Altered expression and activity of various components of the apoptotic pathway, including receptors, ligands, adaptors, and caspases, can contribute to malfunction of the apoptotic machinery and, ultimately, to a more malignant phenotype. Such altered expression is exemplified by the elimination of caspase-8 in high-risk neuroblastomas, the most common group of early childhood tumors (5). Caspase-8 is a key apoptotic factor involved in both the extrinsic and the intrinsic apoptotic pathways (6, 7) (Box 1Go). In the most aggressive, disseminated stage of neuroblastoma, the caspase-8 gene, CASP8, is deleted or silenced by methylation, a change strongly associated with amplification of the MYCN gene, a known molecular marker of poor prognosis (8, 9). Highly aggressive neuroblastomas are generally unresponsive to treatment and account for most of the pediatric cancer deaths (5). The overall loss of caspase-8 expression in neuroblastomas is estimated to be 25–35% and up to 70% in highly aggressive tumors (5, 9).


Box 1. The Two Major Apoptotic Pathways: Extrinsic (Death Receptor-Induced) and Intrinsic (Mitochondrial, Stress-Induced)

The extrinsic pathway is initiated by ligation of transmembrane death receptors belonging to the tumor necrosis factor (TNF)-receptor family (e.g., Fas/Apo-1/CD95, TNF-R1 or TRAMP), and the assembly of the death-inducing signaling complex (DISC). The DISC is the site of activation for caspase-8. Apoptosis through the extrinsic pathway is responsible for eliminating cells during development and immunosurveillance (6). The intrinsic pathway becomes activated upon response to ionizing radiation, chemotherapeutic agents and mitochondrial damage, leading to cytochrome c release and recruitment of caspase-9 into an "apoptosome." Once activated, caspase-9 can cleave and activate other caspases, including caspase-8 (7).

 

A recent study by Stupack et al. investigated the effects of caspase-8 deletion on the metastatic potential of neuroblastomas (10). The authors utilized a chorioallantoic membrane (CAM) model, a widely utilized in vivo experimental system for studying tumor cell metastasis in which tumor cells are grafted onto the highly vascularized chorioallantoic membrane of the developing chick embryo through an opening in an egg shell (11). This model has some limitations owing to the instability of embryonic tissue (12) and the requirement that the CAM must be wounded in order for the tumor cells to migrate (13). At the same time, this a convenient system which allows one to assess tumor growth, invasion, and spontaneous metastasis within the same animal—events not as readily achieved in mouse models of neuroblastoma (14). The CAM system has been used by several groups for semiquantitative assessment of metastasis (15–18) and, in combination with real time polymerase chain-reaction (PCR), allows for a highly sensitive and quantitative detection of the metastatic dissemination of tumor cells (11). Utilizing this quantitative technique, Stupack et al. report a much higher incidence of apoptosis in caspase-8+, locally invasive extratumoral cells as compared to caspase-8– cells. Conversely, knockdown of caspase-8 expression by RNA interference promotes metastasis but has no effect on primary tumor growth. Their hypothesis that loss of caspase-8 promotes metastatic disease is further validated in mice, where decreased levels of caspase-8 mRNA are observed in metastases.

Caspase-8 expression is a key determinant of sensitivity to apoptosis induced by death-inducing ligands or cytotoxic drugs (19)—apoptosis that is mediated through the extrinsic pathway. Decreases in or an absence of caspase-8 mRNA and protein render neuroblastoma cell lines resistant to apoptosis induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), CD95-specific antibody, or TNF-{alpha} (8, 19). This raises an intriguing question: do caspase-8–expressing neuroblastoma cells die in a death receptor-dependent manner? The study by Stupack et al. provides evidence for increased apoptosis in the absence of pro-apoptotic cycloheximide in caspase-8–expressing cells in vivo (10). Cycloheximide is known to augment the effect of death ligands and pre-sensitize neuroblastoma cells to death-receptor-mediated killing (8, 9). In the study by Stupack et al., an in vitro treatment with cycloheximide led to an increased apoptosis in caspase-8+ cells as compared to caspase-8– cells; however, no difference in the rates of apoptosis among these cell lines was detected in the absence of cycloheximide (10). Therefore, an increase in apoptosis in caspase-8+ cells in the absence of cycloheximide in vivo, in combination with previous results showing that etoposide- and staurosporine-mediated death does not depend on caspase-8 expression (10, 20), might suggest that caspase-8–expressing neuroblastomas undergo apoptosis in a caspase-8–dependent manner that is independent of death receptor activation.

One such form of stress response- and death receptor-independent apoptosis is integrin-mediated death (IMD), a process that occurs in adherent cells and, thus, is distinct from anoikis, a form of programmed cell death resulting from a loss of integrin-mediated cell-matrix contact (21). IMD results from altered clustering of integrins and depends on the ability of the integrin ß-subunit to recruit and activate caspase-8 at the cell surface (22). IMD may also depend on activity of protein kinase A (PKA), which can activate caspase-8 when integrin ligation (but not cell adherence) is perturbed (23) as a result of integrins failing to bind their ECM ligands (Figure 1Go). For instance, {alpha}vß3-expressing endothelial cells undergo rapid apoptosis when seeded in a three-dimensional collagen I matrix (which does not ligate the {alpha}vß3 integrin) or upon treatment with an {alpha}vß3 integrin antagonist (22, 24). Conversely, inhibitors of caspase-8, but not inhibitors of caspase-9, restore neovascularization in tissues treated with an {alpha}vß3 integrin antagonist, suggesting that {alpha}vß3-mediated apoptosis is caspase-8–dependent (22). A similar association between unligated {alpha}vß3 integrins and abundant caspase-8 expression has been linked to the regulation of osteoclast apoptosis (25).

In addition to being affected by {alpha}vß3 integrins, apoptotic signaling pathways are triggered by non-ligation or antagonism of ß1 integrins (22). For example, ß1 integrin signaling has been implicated in mediating resistance to chemotherapy in cancers of lung, colon, and breast (26–28); a recent study by Park et al. showed that ß1 integrin antagonism is a promising therapeutic approach in breast cancer therapy (29). In neuroblastoma, tumors with poor prognosis lack integrins with ß1 subunits, consistent with increased apoptosis in the presence of ß1. It is interesting to note that there is an inverse relationship between the loss of ß1 integrin and overexpression of N-myc, whose expression is associated with silencing of CASP8 (30, 31). Coincidentally, the report by Stupack et al. demonstrated that caspase-8 co-precipitates with unligated ß1 integrins from neuroblastoma cells, and neuroblastoma cells expressing caspase-8 undergo apoptosis on collagen I, a matrix which is not a ligand for the integrins ({alpha}3ß1, {alpha}5ß1, or {alpha}vß5) expressed on these cells (10). Further investigation of {alpha}3ß1 integrin, the most abundant receptor on the cell lines analyzed in the Stupak et al. study, revealed that {alpha}3ß1 antagonism selectively enhances apoptosis of caspase-8-expressing neuroblastoma cells and prevents their metastasis in vivo.

The above findings indicate that neuroblastoma cells can escape IMD either by loss of caspase-8 or by antagonism or unligation of specific integrins. Historically, integrins have been shown to promote cell survival by mediating cellular adhesion to the ECM (32). The recent findings by Stupack et al. (10) suggest a new role for integrins in tumor invasion and metastasis. Integrins seem to have a capacity to selectively suppress or promote apoptosis depending on the environmental cues they receive from ECM. Their life- or death-promoting activities depend on the presence of suitable ligands, which places them in a newly appreciated category of apoptotic triggers: the dependence receptors (22, 33). These phenomena are most likely responsible for the discrepancies in the literature regarding the roles of {alpha}5ß1 integrin, a fibronectin receptor (Figure 1Go). {alpha}5ß1 has been shown in some studies to induce metastasis and correlate with poor prognosis, yet in other studies to suppress tumorigenicity and angiogenesis (22), perhaps depending on interactions with different ECMs.

Caspase-8 seems to function downstream of unligated integrins (22), and suppression of its activity might represent the mechanism by which neuroblastoma cells overcome IMD, survive, and metastasize (10). Because integrins govern so many different aspects of normal cell functions, it is only natural to speculate that in addition to direct activation of caspase-8 they might also have an indirect effect on caspase-8-mediated apoptosis through interaction with other signaling molecules. Some of the possible direct and indirect interactions between integrins and caspase-8 are illustrated in Figure 2Go. For example, integrin signaling increases the expression of the caspase-8 inhibitor c-FLIP (Fas-associated death domain–like interleukin 1ß–converting enzyme (FLICE)-inhibitory protein) (2), and overexpression of anti-apoptotic c-FLIP has been demonstrated in high-stage neuroblastoma (34). In addition, human keratinocytes, which undergo apoptosis as a result of ß1 integrin antagonism, fail to die when they overexpress c-FLIP (35). Bcl-2, a known inhibitor of the intrinsic apoptotic pathway can bind and sequester caspase-8 (36). Bcl-2 is frequently expressed in neuroblastoma cells and its presence inversely correlates with apoptosis (34). Interestingly, the expression of {alpha}5ß1 integrins or {alpha}vß3 integrins by neuroblastoma cells can induce expression of bcl-2, a process promoting survival (37). Integrin antagonism may activate the tumor suppressor p53, which forms a complex with caspase-8, thus suggesting involvement of p53 in IMD (22).


Figure 2
View larger version (26K):
[in this window]
[in a new window]
  		Figure 2. Simplified schematic of apoptosis pathways focused on integrin-mediated death (IMD). Integrins ligated by the appropriate ligands serve to mediate cell survival pathways (purple). In their unligated or antagonized state, integrins promote the recruitment and activation of caspase-8 at the cell surface. This results in initiation of the IMD pathway (red), which occurs independently of the death receptor-mediated extrinsic pathway (blue) or stress-induced intrinsic pathway (green). Integrin antagonism can potentiate caspase-8 activity by activating protein kinase A (PKA), which in turn activates caspase-8, or by suppressing the expression of inhibitors, c-FLIP and bcl-2. c-FLIP, Fas-associated death domain–like interleukin 1ß–converting enzyme (FLICE)-inhibitory protein.

 
Many cytotoxic drugs induce caspase-8-dependent apoptosis, thus the loss of caspase-8 in neuroblastoma might represent an important determinant of resistance to chemotherapy. Sensitivity to chemotherapy depends not only on genetic alterations of the tumor cell but also on the tumor microenvironment. Tumor cells are more dependent on suppression of apoptosis than other cells—a strong rationale for employing pro-apoptotic strategies to restore sensitivity to chemotherapeutics. Many of the novel therapeutics currently in development do, indeed, target components of the caspase-8-dependent IMD pathway and they include among others direct modulators of caspase-8 expression (e.g., interferon gamma) as well as c-FLIP, members of the bcl-2 family, and the caspase-8 inhibitors termed X-linked inhibitor of apoptosis protein (XIAP) and survivin (38). Several integrin inhibitors are also under investigation for their possible use as therapeutic agents (24). As recent advances improve our understanding of molecular mechanisms regulating metastatic processes, we also have to keep in mind they raise more questions than they answer. Complex and sometimes redundant pathways and interactions among tumor cells, host cells and the surrounding ECM require that the therapeutic targets are chosen carefully, as in addition to exerting response in the tumor cells they will likely affect other important physiological functions.


Figure 3
Bonnie F. Sloane, PhD, is Distinguished Professor and Chair of the Department of Pharmacology at Wayne State University in Detroit. She received her BS and MA from Duke University and her PhD in Physiology from Rutgers. She is internationally recognized for her research examining proteolytic enzymes and their impact on the progression of breast cancer and is a leader in applying imaging to the analysis of proteolytic enzymes in cancers. She co-founded the International Proteolysis Society as well as the Protease Consortium. Her research has been honored nationally through her selection as one of the four initial Avon Foundation/AACR International Scholar Hosts for Breast Cancer Research and she is director of a Department of Defense Breast Cancer Center of Excellence. She also serves as special advisor to the NCI Cancer Imaging Program. E-mail: bsloane{at}med.wayne.edu; fax (313) 577-6739.


Figure 4
Izabela Podgorski, PhD, is a post-doctoral research associate in Bonnie F. Sloane’s laboratory in the School of Medicine at Wayne State University. She received a postdoctoral fellowship from the Department of Defense to support her research on molecular mechanisms underlying the metastasis of prostate cancer to bone. E-mail: ipodgors{at}med.wayne.edu

References:

  1. Cahill, D.P., Kinzler, K.W., Vogelstein, B., and Lengauer, C. Genetic instability and darwinian selection in tumours. Trends Cell Biol. 9, M57–M60 (1999).[CrossRef][Medline]
  2. Stupack, D.G. and Cheresh, D.A. Get a ligand, get a life: Integrins, signaling and cell survival. J. Cell Sci. 115, 3729–3738 (2002).[Abstract/Free Full Text]
  3. Miranti, C.K. and Brugge, J.S. Sensing the environment: A historical perspective on integrin signal transduction. Nat. Cell Biol. 4, E83–E90 (2002).[CrossRef][Medline]
  4. Hanahan, D. and Weinberg, R.A. The hallmarks of cancer. Cell 100, 57–70 (2000). This paper is an excellent comprehensive review on complexity of human cancer.[CrossRef][Medline]
  5. van Noesel, M.M. and Versteeg, R. Pediatric neuroblastomas: Genetic and epigenetic "danse macabre." Gene 325, 1–15 (2004).[CrossRef][Medline]
  6. Boatright, K.M. and Salvesen, G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 15, 725–731 (2003). This paper is a great overview of apoptotic pathways focusing on mechanisms of caspase activation, and introducing proximity-induced dimerization as a distinct mechanism for activation of initiator caspases.[CrossRef][Medline]
  7. Kruidering, M. and Evan, G.I. Caspase-8 in apoptosis: The beginning of "the end"? IUBMB Life 50, 85–90 (2000).[CrossRef][Medline]
  8. Teitz, T., Lahti, J.M., and Kidd, V.J. Aggressive childhood neuroblastomas do not express caspase-8: An important component of programmed cell death. J. Mol. Med. 79, 428–436 (2001). This paper reported that the re-introduction of caspase-8 re-sensitizes neuroblastoma cells to apoptosis, and suggested caspase-8 is a tumor suppressor.[CrossRef][Medline]
  9. Teitz, T., Wei, T., Valentine, M.B. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6, 529–35 (2000). This paper was first to report that caspase-8 gene is silenced in neuroblastoma through DNA methylation or gene deletion.[CrossRef][Medline]
  10. Stupack, D.G., Teitz, T., Potter, M.D., Mikolon, D., Houghton, P.J., Kidd, V.J., Lahti, J.M., and Cheresh, D.A. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439, 95–99 (2006).[CrossRef][Medline]
  11. Zijlstra, A., Mellor, R., Panzarella,G., Aimes, R.T., Hooper, J.D., Marchenko, N.D., and Quigley, J.P. A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res. 62, 7083–7092 (2002).[Abstract/Free Full Text]
  12. Tufan, A.C. and Satiroglu-Tufan, N.L. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. Curr. Cancer Drug Targets 5, 249–66 (2005).[CrossRef][Medline]
  13. Ossowski, L. In vivo invasion of modified chorioallantoic membrane by tumor cells: The role of cell surface-bound urokinase. J. Cell Biol. 107 (6 Pt 1), 2437–2445 (1988).[Abstract/Free Full Text]
  14. Beltinger, C. and Debatin, K.M. Murine models for experimental therapy of pediatric solid tumors with poor prognosis. Int. J. Cancer 92, 313–318 (2001).[CrossRef][Medline]
  15. Chambers, A.F., Shafir, R., and Ling, V., A model system for studying metastasis using the embryonic chick. Cancer Res. 42, 4018–4025 (1982).[Abstract/Free Full Text]
  16. Ossowski, L. and Reich, E. Experimental model for quantitative study of metastasis. Cancer Res. 40, 2300–2309 (1980). This is the original paper introducing the CAM model as a system to study metastasis.[Abstract/Free Full Text]
  17. MacDonald, I.C., Schmidt, E.E., Morris, V.L., Chambers, A.F., and Groom, A.C. Intravital videomicroscopy of the chorioallantoic microcirculation: A model system for studying metastasis. Microvasc Res. 44, 185–99 (1992).[CrossRef][Medline]
  18. Kim, J., Yu, W., Kovalski, K., and Ossowski, L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94, 353–362 (1998). This paper was first to report a PCR amplification of human alu sequences in combination with the CAM system as a tool to semiquantitatively assess metastasis.[CrossRef][Medline]
  19. Fulda, S., Kufer, M.U., Meyer, E., van Valen, F., Dockhorn-Dworniczak, B., and Debatin, K.M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20, 5865–5877 (2001).[CrossRef][Medline]
  20. Teitz, T., Wei, T., Liu, D., Valentine, V., Valentine, M., Grenet, J., Lahti, J.M., and Kidd, V.J.Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene 21, 1848–1858 (2002).[CrossRef][Medline]
  21. Frisch, S.M. and Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124, 619–626 (1994). This is the first paper to introduce phenomenon of "anoikis."[Abstract/Free Full Text]
  22. Stupack, D.G., Puente, X.S., Boutsaboualoy, S., Storgard, C.M., and Cheresh, D.A. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol. 155, 459–470 (2001). This is among the first papers to suggest integrins as dependence receptors and to reveal their role as proactive mediators of cell death.[Abstract/Free Full Text]
  23. Kim, S., Bakre, M., Yin, H., and Varner, J.A. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J. Clin. Invest. 110, 933–941 (2002).[CrossRef][Medline]
  24. Jin, H. and Varner, J. Integrins: Roles in cancer development and as treatment targets. Br. J. Cancer 90, 561–565 (2004).[CrossRef][Medline]
  25. Zhao, H., Ross, F.P., and Teitelbaum, S.L. Unoccupied alphavbeta3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol. Endocrinol. 19, 771–780 (2005).[Abstract/Free Full Text]
  26. Aoudjit, F. and Vuori, K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20, 4995–5004 (2001).[CrossRef][Medline]
  27. Fujita, S., Watanabe, M., Kubota, T., Teramoto, T., and Kitajima, M. Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett. 91, 145–149 (1995).[CrossRef][Medline]
  28. Sethi, T., Rintoul, R.C., Moore, S.M. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662–668 (1999).[CrossRef][Medline]
  29. Park, C.C., Zhang, H., Pallavicini, M., Gray, J.W., Baehner, F., Park, C.J., and Bissell, M.J. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 2006. 66, 1526–1535 (2006).[Abstract/Free Full Text]
  30. Favrot, M.C., Combaret, V., Goillot, E. et al. Expression of integrin receptors on 45 clinical neuroblastoma specimens. Int. J. Cancer 49, 347–355 (1991).[Medline]
  31. Meyer, A., van Golen, C.M., Kim, B., van Golen, K.L., and Feldman, E.L. Integrin expression regulates neuroblastoma attachment and migration. Neoplasia 6, 332–342 (2004).[CrossRef][Medline]
  32. Schwartz, M.A. Integrins, oncogenes, and anchorage independence. J. Cell Biol. 139, 575–578 (1997).[Free Full Text]
  33. Stupack, D.G. Integrins as a distinct subtype of dependence receptors. Cell Death Differ. 12, 1021–1030 (2005).[CrossRef][Medline]
  34. Poulaki, V., Mitsiades, M., Romero, M.E., and Tsokos, M. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res. 61, 4864–4872 (2001).[Abstract/Free Full Text]
  35. Marconi, A., Atzei, P., Panza, C. Fila, C., Tiberio, R., Truzzi, F., Wachter, T., Leverkus, M., and Pincelli, C. FLICE/caspase-8 activation triggers anoikis induced by beta1-integrin blockade in human keratinocytes. J. Cell Sci. 117(Pt 24), 5815–5823 (20040.[Abstract/Free Full Text]
  36. Kim, P.K., Mahidhara, R., and Seol, D.W. The role of caspase-8 in resistance to cancer chemotherapy. Drug Resist. Update 4, 293–296 (2001).[CrossRef][Medline]
  37. Lee, B.H. and Ruoslahti, E. alpha5beta1 integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and Ca2+/calmodulin-dependent protein kinase IV. J. Cell Biochem. 95, 1214–1223 (2005).[CrossRef][Medline]
  38. Goldsmith, K.C. and Hogarty, M.D. Targeting programmed cell death pathways with experimental therapeutics: Opportunities in high-risk neuroblastoma. Cancer Lett. 228, 133–141 (2005).[CrossRef][Medline]




This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Podgorski, I.
Right arrow Articles by Sloane, B. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Podgorski, I.
Right arrow Articles by Sloane, B. F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.